Yesterday, PolyMedix, Inc. announced the appointment of Steffen Helmling, Ph.D. as their new Vice President of Business Development. Dr. Helmling will be responsible for new development initiatives, such as partnering and licensing for PolyMedix’s products in development.
PolyMedix is a biotech company focused on developing new pharmaceuticals for the treatment of infectious diseases and cardiovascular disorders. PolyMedix’s lead antibiotic, MX-30063, is in Phase 2 clinical trials, and its lead heptagonist compound, PMX-60056, has completed Phase 1 trials. Their PolyCides products are intended to be used as additives to such items as paints, plastic and textile to create self-sterilizing surfaces.
Dr. Helmling’s previous position was at Noxxon Pharma, Inc., where he most recently served as Executive Vice President, Business Development. During his time at Noxxon, Helmling worked with such companies as Pfizer, Roche, and Eli Lilly. He has a Master’s in Biology from Bowling Green State University, and a Ph.D. in biochemistry from Tufts University.
“We are pleased to have Steffen join our management team,” said Nicholas Landekic, President and CEO of PolyMedix. “He brings an impressive background in negotiating licensing agreements, managing partnerships, and conducting market assessments. His expertise and track record of achievements will be a major asset as we advance our programs through the clinic and continue to explore opportunities for partnerships with pharmaceutical companies.”
Let us hear your thoughts below: